Adaptive Biotechnologies Included in Key Abstracts at ASCO 2022 Supporting the Role of the clonoSEQ® Assay as a Standard for MRD Assessment Technology
June 02, 2022 16:10 ET
|
Adaptive Biotechnologies
SEATTLE, June 02, 2022 (GLOBE NEWSWIRE) -- Data from Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive...
OBI Pharma Announces Poster Presentations at the 2022 ASCO Annual Meeting for Adagloxad Simolenin, OBI-999, OBI-3424, and Exhibition Booth
May 17, 2022 05:00 ET
|
OBI Pharma Inc.
TAIPEI, Taiwan, May 17, 2022 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (TPEx: 4174), a leader in First-in-Class Cancer therapeutics, today announced that data highlighting ongoing clinical studies...